Oppgang i dag, hva skyldes det?
Over 8% opp i dag, gledelig for oss som har sittet en stund uten nyheter. Men hva skyldes den plutselige oppturen? Jeg tipper at siden trvx er tatt inn i hovedindeksen, så må vel alle indeksfond som speiler indeksen ta inn trvx? (korriger meg om feil) Eller er det bare en korrigering opp som følge av en alt for bratt nedtur i det siste? (hjulpet av arc sin 'analyse')
mvh
liverpudlian
mvh
liverpudlian
Redigert 20.01.2021 kl 19:53
Du må logge inn for å svare
mozel
30.11.2017 kl 10:13
2552
Savner kommentar fra de som vet6 det meste om Targovax
Redigert 20.01.2021 kl 19:53
Du må logge inn for å svare
Corelli
30.11.2017 kl 15:33
2479
kansje dette : Published: 14:03 CET 30-11-2017 /GlobeNewswire /Source: Targovax ASA / : TRVX /ISIN: NO0010689326
Targovax ASA: New member of the board of directors
Oslo, Norway, 30 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the extraordinary general meeting of Targovax ASA has today appointed Patrick Vink as the new chairman of the board of directors.
The previous chairman of the board, Jónas Einarsson, replaces Lars Lund-Roland as an ordinary member of the board of directors.
The board of directors of Targovax ASA will now have the following members:
Patrick Vink (chairman);
Jónas Einarsson;
Bente-Lill Romøren;
Per Samuelsson;
Robert Burns;
Johan Christenson;
Eva-Lotta Coulter; and
Diane Mary Mellett.
Patrick Vink, the new chairman of the board, commented: "I am thrilled to be joining the Board at such an important time for the Company. Targovax is building a pioneering pipeline of immunotherapy drugs focused on hard-to-treat cancers with a significant unmet medical need. I hope to bring valuable experience to the Board and guide the business into becoming a leading immuno-oncology company focused on the discovery, development and delivery of first-in-class treatments to those who need them most."
Targovax ASA: New member of the board of directors
Oslo, Norway, 30 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the extraordinary general meeting of Targovax ASA has today appointed Patrick Vink as the new chairman of the board of directors.
The previous chairman of the board, Jónas Einarsson, replaces Lars Lund-Roland as an ordinary member of the board of directors.
The board of directors of Targovax ASA will now have the following members:
Patrick Vink (chairman);
Jónas Einarsson;
Bente-Lill Romøren;
Per Samuelsson;
Robert Burns;
Johan Christenson;
Eva-Lotta Coulter; and
Diane Mary Mellett.
Patrick Vink, the new chairman of the board, commented: "I am thrilled to be joining the Board at such an important time for the Company. Targovax is building a pioneering pipeline of immunotherapy drugs focused on hard-to-treat cancers with a significant unmet medical need. I hope to bring valuable experience to the Board and guide the business into becoming a leading immuno-oncology company focused on the discovery, development and delivery of first-in-class treatments to those who need them most."
Redigert 20.01.2021 kl 19:53
Du må logge inn for å svare